Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – Here’s What Happened

Tyra Biosciences, Inc. (NASDAQ:TYRA) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $23.08 and last traded at $22.27, with a volume of 55492 shares. The stock had previously closed at $21.50.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Raymond James Financial started coverage on Tyra Biosciences in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a research note on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Tyra Biosciences Stock Performance

The company has a market capitalization of $1.19 billion, a PE ratio of -11.92 and a beta of 1.09. The stock has a 50 day moving average price of $16.84 and a two-hundred day moving average price of $13.01.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.50). Sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In other news, Director Robert J. More sold 246,871 shares of Tyra Biosciences stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $20.25, for a total value of $4,999,137.75. Following the transaction, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. The trade was a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 15.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. Federated Hermes Inc. increased its stake in Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares during the last quarter. US Bancorp DE grew its holdings in shares of Tyra Biosciences by 50.5% in the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after acquiring an additional 1,823 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences in the third quarter valued at about $133,000. Russell Investments Group Ltd. raised its holdings in Tyra Biosciences by 27.7% during the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after acquiring an additional 2,766 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.